Zobrazeno 1 - 10
of 516
pro vyhledávání: '"David G, Maloney"'
Autor:
Carla S. Walti, Elizabeth M. Krantz, Joyce Maalouf, Jim Boonyaratanakornkit, Jacob Keane-Candib, Laurel Joncas-Schronce, Terry Stevens-Ayers, Sayan Dasgupta, Justin J. Taylor, Alexandre V. Hirayama, Merav Bar, Rebecca A. Gardner, Andrew J. Cowan, Damian J. Green, Michael J. Boeckh, David G. Maloney, Cameron J. Turtle, Joshua A. Hill
Publikováno v:
JCI Insight, Vol 6, Iss 11 (2021)
BACKGROUND Little is known about pathogen-specific humoral immunity after chimeric antigen receptor–modified T (CAR-T) cell therapy for B cell malignancies.METHODS We conducted a prospective cross-sectional study of CD19-targeted or B cell maturati
Externí odkaz:
https://doaj.org/article/e8eb2b57fba84a3cb68dc70fadfe02d3
Autor:
Darrell R. Fisher, Ryan D. Cassaday, David G. Maloney, Ted Gooley, Damian J. Green, Sherilyn A. Tuazon, Stephen D. Smith, Victor A. Chow, Manuela Matesan, Brenda M. Sandmaier, Oliver W. Press, Johnnie J. Orozco, Ajay K. Gopal
Publikováno v:
Blood Advances
Key Points Megadose radioimmunotherapy with 90Y-ibritumomab tiuxetan treats relapsed/refractory aggressive BCLs safely and successfully.Radioimmunotherapy conditioning regimens warrant further exploration for curative-intent treatment in relapsed/ref
Autor:
David G. Maloney, Mazyar Shadman
Publikováno v:
Hematology/Oncology Clinics of North America. 35:847-862
Despite significant improvement in clinical outcomes of chronic lymphocytic leukemia (CLL), patients who experience failure of Bruton tyrosine kinase inhibitors or venetoclax benefit from immune therapy approaches. Allogeneic transplant is a potentia
Autor:
David G. Maloney, Jordan Gauthier
Publikováno v:
Hematology/Oncology Clinics of North America. 34:957-970
Mantle cell lymphoma (MCL) accounts for fewer than 10% of non-Hodgkin lymphoma. There is a high initial response rate to chemotherapy and rituximab, but a nearly universal risk of relapse. Allogeneic hematopoietic cell transplantation (allo-HCT) prov
Autor:
Noa Granot, Brenda M. Sandmaier, Barry E. Storer, David G. Maloney, Rainer Storb, Barbara S. Pender, Andrew R. Rezvani
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:1811-1818
We previously reported a 24% 1-year relapse rate in 93 older or medically unfit patients with CD20+ B cell malignancies after allogeneic hematopoietic cell transplantation (HCT) with low-intensity conditioning. The current prospective study tested th
Autor:
Scott J. Rodig, Mikel Lipschitz, Elizabeth Budde, Jeremy S. Abramson, Jonathon B. Cohen, Utkarsh Acharya, Michael Rogalski, Jerome Ritz, Yusuke Kamihara, Pei Hsuan Chen, Matthew J. Frigault, Stephen D. Smith, Bradley D. Hunter, Marcela V. Maus, Sarah Nikiforow, Joseph E. Maakaron, Philippe Armand, Matthew Mei, Alex F. Herrera, Robert A. Redd, Justin Kline, Ajay K. Gopal, Yi-Bin Chen, Caron A. Jacobson, Samantha Jaglowski, Kyle Wright, David G. Maloney
Publikováno v:
Journal of Clinical Oncology. 38:3095-3106
PURPOSE Axicabtagene ciloleucel (axi-cel) was approved by the Food and Drug Administration for relapsed aggressive B-cell non-Hodgkin lymphoma in part on the basis of durable remission rates of approximately 40% in a clinical trial population. Whethe
Autor:
Noriko Fukuhara, David G. Maloney, Hiya Banerjee, Miguel Izquierdo, Janet Lasher, Jaclyn Davis, Michinori Ogura, Kensei Tobinai
Publikováno v:
Blood Adv
Because of high relapse rates with rituximab combinations, there is an unmet need for new therapeutic agents for treatment of indolent B-cell non-Hodgkin lymphoma (iNHL) or follicular lymphoma (FL). In previous trials, ofatumumab in combination with
Autor:
Elisha S. Rusch, Richard T. Maziarz, David G. Maloney, Junlong Li, Vadim V. Romanov, Frederick L. Locke, James Signorovitch, Stephen J. Schuster
Publikováno v:
Blood Advances. 4:1432-1439
Chimeric antigen receptor T-cell (CAR-T) therapy yields durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Cytokine release syndrome (CRS) is a CAR-T therapy–related adverse event. To date, clinical tr
Autor:
James Signorovitch, Frederick L. Locke, Vadim V. Romanov, Elisha S. Rusch, David G. Maloney, Stephen J. Schuster, Richard T. Maziarz, Junlong Li
Publikováno v:
Blood Advances. 4:1440-1447
Chimeric antigen receptor-T (CAR-T) cell therapy achieves durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL), but may be associated with neurological toxicity (NT). We retrospectively assessed differences
Autor:
Yi Bin Chen, Stephen J. Forman, Alex F. Herrera, Joseph H. Antin, Philippe Armand, Auayporn Nademanee, Lu Chen, David G. Maloney, Sirin Khajavian, Matthew L Chase, Vincent T. Ho, Robert J. Soiffer, Mazyar Shadman, Justin Darrah
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:2383-2387
Background: Primary mediastinal large B-cell lymphoma (PMBCL) is a subset of aggressive B-cell non-Hodgkin lymphoma (B-NHL) with distinct biological and clinical features. Although most patients are cured with frontline chemoimmunotherapy with or wit